Power range and 10,000-hour lifetime reliability leads industry

HAYWARD, California, Sept. 6, 2018 /PRNewswire/ — RayVio Corp., an advanced health and hygiene company, is volume shipping its new, 280nm XD mid-power and XR high-power UV-C LEDs and established industry-leading, 10,000 hour benchmarks for lifetime reliability – critical to the success of consumer and medical-grade solutions. Both the XD and XR Series are available as standard 3535 emitters or mounted on star boards for easy test development and product integration. Both devices are in-stock at Digi-Key.

The XD and XR series are available from Digi-Key as emitters or on star board. Both have a nominal drive current of 100mA and can be over or under driven to optimize for power or lifetime. XD Series: Typical Output 3-5 mW. XR Series: Typical Output 6-18+ mW.

“We are excited to have RayVio as our exclusive provider of UV-C LEDs and recognize their continuing leadership in the industry for both lifetime and performance,” said Nick Olson, Manager, Semiconductor Product Group at Digi-Key Electronics.  “We are already stocking both the XD and XR Series and are well equipped to help our customers from a technical stand point as the demand for UV-C continues to grow!”

For the first time in the industry, RayVio is introducing documented lifetime ratings at multiple currents for both the XD and XR devices. This allows designers to engineer solutions for optimum performance, lifetime, and reliability characteristics for their particular application.

“These are the most cost-effective UV-C LEDs available and that means more opportunity to develop new solutions,” said Dr. Robert C. Walker, CEO. “For applications where cost is the primary driver, the XD mid-power Series is optimum and when milliwatt-power is the priority, our XR Series with up to twelve milliwatts of power is superior and yet very cost effective on a $/mW basis.”

Regardless of drive current, RayVio’s UV-C LEDs have demonstrated Sterility Assurance Levels of 10^-6 or 99.9999% and can be applied to applications from surface and water disinfection to medical-grade sterilization.

The XD and XR Series are in volume production and globally available from Digi-Key.

About RayVio Corp.
RayVio Corp. is an advanced health and hygiene company that delivers clean water and environments. RayVio helps protect billions from germs and creates new markets and revenue streams by enabling a new class of products. Its powerful and efficient UV LED technology can be integrated into a variety of applications, powering versatile on-demand solutions that give consumers control over health without chemicals or costly consumables. To learn more, please visit www.rayvio.com.

Photo – https://mma.prnewswire.com/media/738134/RayVio_XR_Series_200.jpg
Logo – https://mma.prnewswire.com/media/372098/RayVio_Corporation_Logo.jpg

SEOUL, South Korea, Sept. 6, 2018 /PRNewswire/ — JLK Inspection (CEO Wontae Kim), a member company of the K-ICT Born2Global Centre, announced that its ischemic stroke diagnosis-supporting software JBS-01K has been first approved by Ministry of Food and Drug Safety (MFDS) of South Korea as an AI-based class III computer aided diagnosis system.

Caused by a blood clot in patients’ brain, ischemic stroke leads them to aftereffects and reduced performance in exercise ability. As South Korea is becoming an aging society, it is expected that the number of ischemic stroke patients will increase rapidly. Ischemic stroke has different treatments and prognosis by its occurrence subtypes, thus it is crucial to identify the stroke subtype. To analyze brain MR images of patients enables exact stroke subtype classification, quick and appropriate treatments, and a better prognosis.

JBS-01K is developed by JLK Inspection’s own AI technology. It is an AI-based medical image diagnosis-supporting system which assists medical specialists in diagnosing the cause of ischemic stroke more than detecting brain lesions. When brain MR images and atrial fibrillation presence of patients are entered into JBS-01K, this software shows the probability of four ischemic stroke subtypes to support the physicians and their diagnosis.

The MFDS of South Korea uses a four-class classification of medical devices by their intended use and potential hazard to human. More specifically, an AI-based medical device is classified according to how the device shows the diagnosis results. ‘Computer aided diagnosis software’, which analyzes medical images and automatically shows the probability of presence, severity, or condition of the diseases, is classified as class III, while class II includes ‘analyzer, medical image, software’ and ‘computed aided detection system’ which shows the area of medical images.

JBS-01K is currently the only medical device classified as ‘computer aided diagnosis software’ (A26430.14) and approved by the MFDS through a large-scale and multi-center clinical trial for safeness and effectiveness.

In 2017, the first investigation application of AI-based medical device in class III for JBS-01K was approved by the MFDS. The multi-center clinical trial was conducted for five months at Dongguk University Ilsan Hospital and Seoul National University Bundang Hospital, and it used the medical data of 1,089 subjects, which was a large-scale clinical trial the world had never seen before regarding AI-based medical device.

The clinical trial was conducted to compare neurologists and JBS-01K independently in terms of the diagnosis results of ischemic stroke subtypes. Assuming JBS-01K as the medical specialist level, an evaluation of the results to check the agreement between JBS-01K and neurologists did prove that performance of the AI-based software is as high as the level of medical specialists according to the multi-center clinical trial with 1,089 subjects.

Made by using big data of brain MR images and clinical information together with the team of neurology professor Dong-Eog Kim of Dongguk University Ilsan Hospital, JBS-01K can provide a data-based quantitative analysis of ischemic stroke subtypes and help the physicians to give patients personalized diagnoses and proper treatments. The use of JBS-01K is expected to improve the prognosis and the life of each patient and reduce the social cost of a nation. In the case of South Korea, the number of MRI units per each million people is 26.3, which ranks fourth according to the OECD data in 2015. This is why JBS-01K is expected to be widely used in not only big hospitals but many medical institutions with MRI units in South Korea.

Meanwhile, JLK Inspection has applied for FDA Approval Submission for JBS-01K and is finding various ways to enter the overseas market such as China and Europe with its international partners.

In addition to JBS-01K, JLK Inspection has built CT-based and MRI-based solutions which cover the whole range of hyperacute and acute cerebrovascular diseases. An AI-based dementia diagnosis platform is currently in development and it will be released in the market to treat the patients as soon as possible. JLK Inspection becomes a global leader in the medical industry with their own AI technology development to save people against varied diseases professionally.

For more detailed information on JLK INSPECTION, visit www.jlk-inspection.com

About JLK INSPECTION

JLK INSPECTION (www.jlk-inspection.com), established in 2014, is Korean leading AI solution company specializing in combining artificial intelligence and image-processing technologies. JLK Inspection is expanding its business scope to build an AI-based general and universal medical platform to cover various diseases and conditions such as brain stroke, brain aneurysm, dementia, prostate cancer, lung cancer and digital pathology, among others, by working in close cooperation with globally renowned hospitals and research centers.

For more information:

Jina Lee
E-mail: jlee@born2global.com

View original content with multimedia:http://www.prnewswire.com/news-releases/ai-based-class-iii-medical-device-of-jlk-inspection-first-approved-by-ministry-of-food-and-drug-safety-of-south-korea-300707711.html

Infinitus (China), the sole sponsor of the event, brings new health solutions to Kazakhstan

ASTANA, Kazakhstan, Sept. 8, 2018 /PRNewswire/ –The “One Belt, One Road” China-Kazakhstan Intelligence Media Forum is being held in Astana, the capital of Kazakhstan, on September 7, 2018, bringing together representatives from the Chinese and Kazakhstan governments, as well as policy institutes, media outlets and companies from the two countries. At the Forum, attendees discussed how to strengthen cooperation and promote cultural exchanges between the two countries. The Forum was co-hosted by the China Public Diplomacy Association, the International Relations Committee of Kazakhstan and International Secretariat of G-Global, and co-organized by huanqiu.com and the Confucius Institute at Eurasian University with Infinitus (China) Company Ltd. serving as the sole sponsor.

2018 marks the fifth anniversary of the launch of China’s “One Belt, One Road” initiative, of which cooperation in healthcare has been a key component. The Forum included the China-Kazakhstan Health Culture and Industry Cooperation Sub-forum, a key topic of which focused on how Chinese manufacturers of traditional Chinese medicines implement their international strategies and establish meaningful collaborations with likeminded organizations in Kazakhstan.

The China-Kazakhstan Health Culture and Industry Cooperation Sub-forum site

“Currently, traditional Chinese medicine (TCM) is playing an important role in propelling mutual learning between eastern and western civilizations among the countries along the route of the Belt and Road initiative, ” said Mr. Wu zhendou, Deputy Director of the International Cooperation Department of the State Administration of Traditional Chinese Medicine of PRC. “It is also becoming an important platform for China and countries along the route to jointly safeguard world peace, enhance human well-being and build a community of shared future for mankind.”

Mr. Lam Yu, Senior Vice President of LKK Health Products Group, Managing Director of Infinitus Global, Vice Chairman and Managing Director of Infinitus (China) Company Ltd., said in his keynote speech, “The global medicine industry has shifted its focus from treatment to prevention, in line with the basic philosophy of traditional Chinese medicine (TCM) which, from its origins, has always advocated that ‘preventing the disease from occurring and worsening is more important than treating a patient already diagnosed with the disease’. When it comes to addressing global health issues, the benefits of TCM, Chinese herbal medicine and health preservation, long a cornerstone of TCM, are increasingly being shown to be an approach with tangible results and worth considering as a solution to the health issues that continue to plague our great planet.”

Mr. Lam Yu gives the keynote speech at the “One Belt, One Road” China-Kazakhstan Intelligence Media Forum

As a leader in the Chinese health sector, Infinitus plans to set up a branch in Kazakhstan within this year. The company has expanded its presence into Canada, Chinese mainland, Hong Kong, Malaysia, Singapore, Taiwan and Thailand, among other countries and regions. Backed by partnerships with leading global universities and colleges as well as scientific research organizations, Infinitus has the capacity to supply products valued at over 50 billion yuan (approx. US$7.5 billion) annually and continues to claim a leading position in terms of market share worldwide.

Mr. Lam Yu added, “Infinitus is willing to provide health solutions to countries along the Belt and Road route and hopes to play a key role in expanding cultural exchanges and partnerships in health between China and Kazakhstan. We will continue to help create an environment for the two countries focused on mutual promotion and development through cooperation, innovation and experience exchange. By doing so, we expect to address the health needs of the people of Kazakhstan, create new job opportunities, boost local economic and social development, as well as deliver the opportunity for the people of Kazakhstan to lead balanced, affluent, harmonious and healthy lives.”

About Infinitus (China) Company Ltd. (http://www.infinitus.com.cn/）

Infinitus (China) Company Ltd., founded in 1992 and headquartered in Guangzhou China, is a member of LKK Health Products Group. The Company focuses on R&D, production, sales and services of Chinese herbal health products. It has set up 30 branches and 30 service centers together with over 7,000 exclusive stores on the Chinese mainland.

Photo – https://photos.prnasia.com/prnh/20180907/2227020-1-a
photo – https://photos.prnasia.com/prnh/20180907/2227020-1-b

Source: Infinitus (China) Company Ltd.

SAN DANIELE DEL FRIULI, Italy, Sept. 7, 2018 /PRNewswire/ —

LimaCorporate, a pioneer and leader in 3D printing of Orthopaedic implants, announces the milestone-based acquisition of TechMah Medical LLC (“TechMah Medical”), a medical device software company located in Knoxville, Tennessee, to complement its hardware portfolio with digital applications.

TechMah Medical was founded in 2014 and focuses on digital technologies dedicated to orthopaedic surgery that impacts the quality of care and fits into today’s cost constraints.  Dr. Mohamed Mahfouz, Professor of Biomedical Engineering at the University of Tennessee, is the founder of TechMah Medical.  Dr. Mahfouz has over 20 years’ experience within Orthopaedics and holds over 300 publications on implant design, imaging, kinematics, sensors, anthropology and forensics. Dr. Mahfouz will continue to be involved with TechMah Medical and will become a long-term partner to LimaCorporate.

The team at TechMah Medical consists of world-class researchers and engineers in bio-wireless electronics, biomechanics, imaging, as well as software and will focus on the release of software and smart instruments which will be used in combination with LimaCorporate implants.

This investment in software know-how, together with the internal 3D printing expertise, brings LimaCorporate to the forefront of digital transformation of the Orthopaedics industry through highly-innovative digital solutions that will change the approach to surgery and standard instrumentation.  

Under the terms of the agreement, LimaCorporate will provide funding to TechMah Medical and complete the acquisition as key product development goals are achieved, becoming the sole shareholder of TechMah Medical over time, while Dr. Mahfouz and his team will remain involved with the business.  Financial terms have not been disclosed.  

“LimaCorporate is the most innovative and agile company in Orthopaedics today and the ideal partner for us to develop our technology and advance the digitization of the industry,” said Dr. Mahfouz from TechMah Medical.

Luigi Ferrari, CEO of LimaCorporate, commented, “We are excited about this transaction and the partnership with Dr. Mahfouz. Combined with our proven implant technology and 3D printing capabilities, this acquisition will allow LimaCorporate to develop a strong foothold in all digital applications surrounding Total Joint Replacement by offering surgeons a new intra-operative experience and by providing their patients flexible personalized care.”

About LimaCorporate  

LimaCorporate is a global medical device company providing reconstructive Orthopaedic solutions to surgeons who face the challenges of improving the quality of life of their patients. Based in Italy, LimaCorporate is committed to the development of innovative products and procedures to enable surgeons to select ideal solution for every individual patient. LimaCorporate’s product range includes large joint revision and primary implants and complete extremities solutions including fixation.

About TechMah Medical  

TechMah Medical LLC is a technology company focused on delivering orthopedic solutions. We build innovative applications designed to improve patient and clinician experience throughout the joint replacement process. Based in Knoxville, Tennessee, our team of scientists and engineers are driven to improve quality and efficiency through customization. 

For additional information on the Company, please visit: limacorporate.com

Limacorporate S.p.A.
Via Nazionale, 52
33038 Villanova di San Daniele
Udine – Italy
T: +39-0432-945511
E: info@limacorporate.com

Source: Limacorporate S.p.A.

SHANGHAI, Sept. 7, 2018 /PRNewswire/ — On September 4, Luye Pharma announced that its independently developed drug, Goserelin Acetate Extended-release Microspheres for Injection (LY01005), has entered phase III clinical trials for prostate cancer in China. Meanwhile, LY01005 is currently under phase I clinical trials in the U.S. via part 505(b) (2) of the United States Federal Food, Drug and Cosmetic Act.

Luye Pharma is working to hasten the launch of LY01005 in China and in other markets around the world, meanwhile advancing its strategic participation in the field of oncology therapeutics. Constantly enriching its R&D pipeline, the company aims to further strengthen its leading position in this field and lay solid foundations for future global market expansion.

Developed by Luye Pharma through its long-acting and extended-release technology platform, LY01005 is a gonadotropin-releasing hormone agonist for the treatment of several conditions, such as prostate cancer, breast cancer and endometriosis. Designed for once-monthly intramuscular administration, LY01005 has similar bioavailability to that of currently marketed drugs, but with better patient compliance and more stable efficacy.

Prostate cancer is one of the most common cancers, with a rate of incidence among the most prevalent of all male cancers in Europe and the United States. In China, incidence of prostate cancer has increased rapidly over the last 10 years. According to IQVIA (formerly known as IMS) data on drug demand, in 2017, total sales revenue for gonadotropin-releasing hormone agonist products in China was about 4.05 billion RMB. Between 2015 and 2017, the compound annual growth rate for this market was 19%. Luye Pharma believes that LY01005 will have a good market prospect after its launch, providing better treatment options for patients in China and around the world. In addition to China and the United States, the company is also working on clinical trial approvals for the drug in Europe and Japan.

Luye Pharma Group acquired the patent for the goserelin microsphere pharmaceutical composition in China, filing a Patent Cooperation Treaty (PCT) application for it in 2014, with patent applications filed in the U.S., Europe, Japan and a number of other countries and regions in 2015; the application for Japan was approved.

Oncology is one of Luye Pharma’s four core therapeutic areas. In addition to the recent progress on LY01005, a number of positive results have been achieved in other pipeline products in the same therapeutic field. For example, LY01013, a IDO/TDO dual-target inhibitor, a new immune-oncology drug independently developed by Luye Pharma, has been approved for Phase I clinical trials in China. LY01008, a Bevacizumab analog indicated for colorectal cancer and non-small cell lung cancer, is progressing smoothly with its Phase III trials. In addition, the company has launched a series of collaborative research and development projects with global leading biotech companies to jointly develop the next generation of therapeutic antibodies for use in immuno-oncology and CAR-T therapy. At present, Luye Pharma has more than ten innovative formulations and drugs in this therapeutic field, which are in different stages of clinical development in China and overseas markets.

As an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative drugs, Luye Pharma has built a rich pipeline across different therapeutic areas, such as central nervous system, metabolism, and cardiovascular diseases. Driven by a strategy of “Global R&D”, the company has established a global R&D network with three R&D centers, located in China, the United States and Europe. Currently, 30 drug candidates are being studied in China and more than 10 are being studied in overseas markets. Luye Pharma has reached advanced world level towards the research of new delivery technology, such as liposome, microsphere and transdermal drug delivery. Moreover, the company has been actively exploring opportunities for the development of innovative compounds and antibodies, cell & gene therapies and smart formulations.

To better leverage R&D results to benefit patients, Luye Pharma has established 7 production bases and more than 30 production lines around the world, as well as a GMP quality management and control systems with international standards. The company has more than 30 marketed products and has presence in more than 80 countries and regions around the world, including China, the United States, Europe, Japan, other major global pharmaceutical markets and high-growth emerging markets. By building high-standard global quality management systems and global operation capacity, Luye Pharma is committed to improving the lives of global patients with ever more high-quality and innovative drugs.

View original content:http://www.prnewswire.com/news-releases/luye-pharmas-goserelin-acetate-extended-release-microspheres-start-phase-iii-clinical-trials-in-china-paralleling-smooth-progress-with-us-regulators-300708679.html

SINGAPORE, Sept. 6, 2018 /PRNewswire/ — Mundipharma has closed an asset purchase agreement with Vital Food Processors Limited, an agricultural science company founded in New Zealand, for the global rights beyond New Zealand to commercialise Zyactinase™ — a clinically-proven gastrointestinal consumer health product.

Zyactinase™ is a freeze-dried extract of Kiwifruit (Actinidia deliciosa) that has been developed as a constipation relief product as well as for long-term gut health. It contains a protease complex, fiber, pectin and fructo-oligosaccharides that stimulates increased bowel movements.

Under the agreement, Mundipharma will initially focus on the commercialising Zyactinase™ to establish a foothold in the US and Canada markets, while continuing to supply existing partners. It will then look to expand its marketing and distribution footprint globally.

This agreement will also enable the extension of the company’s Senokot^® product range in the US, which is also an all natural, clinically proven digestive health supplement for the treatment of constipation.

“We are delighted to have realised this opportunity to acquire a unique, clinically-proven differentiated formulation for commercialisation on a global basis across our network,” said Mundipharma CEO, Raman Singh.

“As well as providing a consumer pathway for a great product, this strategic acquisition also enables us to extend our depth and competitiveness in the digestive health category,” he added.

Dr Oliver Summerfield, Vital Foods CEO and Principal at majority investor Inventages Venture Capital, commented “We believe this deal recognises the value created by Vital Foods’ technology platform and that Mudipharma are a strong partner for the global commercialisation of the clinically-proven digestive health product developed by Vital Foods’ team.”

TM: ZYACTINASE is a trademark of Vital Food

®: SENOKOT is a registered trademark of Purdue in the US.

About Zyactinase™

Zyactinase is reputed to be one of the most effective, gentle laxative therapies currently available. Zyactinase™ is a 100% natural product derived from New Zealand kiwifruit using Vital Foods’ proprietary processing technology with no artificial ingredients. Products formulated with Zyactinase™, including Phloe and Kivia capsules and chewable tablets. Seven separate clinical studies have confirmed that Zyactinase™ formulations improve general digestive health, normalise bowel function, reduce bloating, minimise episodes of occasional constipation, and assist in reducing abdominal pain and discomfort. Zyactinase™ formulations have none of the side effects commonly associated with harsher laxatives.

About Vital Foods

Vital Foods’ was established to provide the digestive health benefits of kiwifruit through easy to consume digestive health products for all ages. The company’s first product on the market was Kiwi Crush™, a frozen kiwifruit drink that is made available to most patients in hospitals and nursing home in New Zealand and is sold as a digestive aid in supermarkets in New Zealand. Vital Foods was formed by two dedicated kiwifruit industry experts and launched by a group of committed local New Zealand investors. Since 2006, Vital Foods’ Research & Development efforts have been financed through a sophisticated syndicate that is predominantly comprised of Inventages Venture Capital and BioPacific Ventures.

About Mundipharma

Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare, including Upper Respiratory Care, Digestive Wellness, Feminine Care, Wound Care and Infection Protection.

For more information please visit: www.mundipharma.com.sg

Logo – https://photos.prnasia.com/prnh/20180906/2228692-1LOGO

SHANGHAI, Sept. 6, 2018 /PRNewswire/ — WuXi AppTec congratulates its partner Hutchison MediPharma (HMP) on receiving approval of fruquintinib capsules (Elunate^®) for metastatic colorectal cancer from the National Medical Products Administration of China (“NMPA”) – formerly the China Food and Drug Administration. Fruquintinib is an innovative medicine that has not previously been launched in China or internationally.

The approval in China was completed using a priority review and approval process, thereby maximizing the number of potential patients who can benefit from this novel cancer treatment. This is the second innovative drug approval in China supported by WuXi STA, a subsidiary of WuXi AppTec, since the implementation of the Marketing Authorization Holder (MAH) pilot program.

Colorectal cancer is a commonly diagnosed cancer worldwide. Approximately 1.36 million new cases and nearly 700,000 deaths are reported each year globally, so the disease represents a significant global healthcare challenge. In China, the annual incidence of colorectal cancer tops 376,000 and continues to grow, and 50% of new cases will eventually develop into metastatic colorectal cancer (mCRC). VEGFR inhibitors play a pivotal role in tumor-related angiogenesis, cutting off the blood supply that a tumor needs to grow rapidly. Fruquintinib (HMPL-013) is a highly selective and potent small-molecule inhibitor of VEGFR 1, 2 and 3, providing a new therapeutic approach for metastatic colorectal cancer patients.

WuXi AppTec provided comprehensive support for the successful market launch of this innovative drug in China using its enabling platforms. WuXi STA, via its industry-leading process development and manufacturing technology platform and global standard quality system, supported the process optimization and process validation of its Active Pharmaceutical Ingredient (API), as well as the Elunate® NDA submission and approval. In June 2018, WuXi STA’s Jinshan API manufacturing site passed the pre-approval inspection by NMPA as part of the Elunate ® NDA application process. WuXi STA also supported fruquintinib capsules’ clinical trials in the United States. In addition, WuXi SMO, a subsidiary of WuXi AppTec, provided services from phase i to phase iii clinical research during the past six years. The entire clinical program of this product was successfully completed, with high data quality and outstanding results obtained. Results of the phase iii study were published on the Journal of the American Medical Association (JAMA) with an impact factor of 47 points.

“We congratulate our partner Hutchison MediPharma on their tremendous achievement. This is the second innovative drug that WuXi STA provided API manufacturing for the approval and launch in China since the implementation of the Marketing Authorization Holder (MAH) pilot program.” said Dr. Minzhang Chen, CEO of STA. “The successful development of fruquintinib is further evidence of our commitment to enabling our partners with the most outstanding capabilities and cutting-edge technologies. We support them in the quest to bring better medicines to patients and strive to fulfill WuXi’s dream that ‘every drug can be made and every disease can be treated’.”

About WuXi AppTec

WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, WuXi platform is enabling nearly 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi’s dream that “every drug can be made and every disease can be treated.” Please visit: http://www.wuxiapptec.com

View original content:http://www.prnewswire.com/news-releases/wuxi-apptec-partner-hutchison-medipharma-receives-approval-of-fruquintinib-capsules-in-china-300707789.html

LUXEMBOURG, Sept. 5, 2018 /PRNewswire/ —

Key appointments strengthen full lifecycle support for pharma  

Inceptua Group (previously Multipharma) today announces the strengthening of its Commercial, Strategy, and Supply Chain teams as industry leading experts Bodil Jonason, Jeremy Broadis, Mark Ware, and Annika Kollén join the company.

“Inceptua is further developing our platform as the partner of choice for pharma and biotech companies commercializing niche and specialty pharma products. We are able to assume partial or full product responsibility, and our offering spans the life-cycle, from pre-approval to product launch and the successful marketing of speciality products. The recruitment of these industry experts augments our position within the areas of Clinical Trial Services, Medicines Access, and Commercial Products and underlines Inceptua‘s drive to provide market leading service throughout the product journey,“ says Alan Raffensperger, CEO, Inceptua Group.:

Bodil Jonason joins as Head of Marketing & Sales for Commercial Products. Bodil is an expert in launching, life cycle management, and commercialization of specialty, rare, and orphan products who joins Inceptua from a role as Vice President at Sobi (Swedish Orphan Biovitrum AB) where she led the Specialty Care unit. Her previous role also included responsibility for the partner product portfolio, making her an experienced alliance partner for companies who wish to launch and commercialize products globally or in selected markets.

Jeremy Broadis has been appointed Vice President, Business Development, Commercial Products. Jeremy has a long and successful track record in assisting companies in bringing their products to patients in key new markets through innovative strategic partnerships.  Jeremy is joining Inceptua from IQVIA (Quintiles) where he was responsible for pan-European specialty products commercialisation. Jeremy also has a background in risk-based transactions (NovaQuest) and healthcare consulting (ZS Associates).

Mark Ware has been appointed Vice President, Strategy for the Inceptua Group and brings over 20 years’ experience in the pharma industry, having worked for Pharma companies, consulting firms and Pharma service providers. His areas of expertise include business development, comparator sourcing, clinical trial supplies, comparator procurement strategy, and preapproval access programs. He has a record of driving growth and most recently lead the Clinical Trial Service teams at Idis and Clinigen.

Furthermore, Inceptua has appointed Annika Kollén as Vice President, Head of Global Supply Chain for the Inceptua Group. Annika is joining Inceptua from a role as Head of Global Supply Chain at Sobi. Annika has significant experience and is considered a leading industry expert within international supply chain management.

“With Bodil Jonason‘s, Jeremy Broadis‘ and Mark Ware‘s experience, broad knowledge, and appreciated leader-ship skills, we add to our team three of the industry‘s leading experts to manage our commercial and strategic efforts. Our supply chain set-up has always been one of our key strengths, and with Annika Kollén joining, we will continue to provide our clients with a best-in-class service and cutting-edge supply chain solutions,“ says Alan Raffensperger.

For further information, please contact:

Inceptua Group Communications
Miranda McLaughlan, Communications Manager
Phone: +49-30-1202-1353
E-Mail: miranda.mclaughlan@inceptua.com

HONG KONG, Sept. 5, 2018 /PRNewswire/ — Hong Kong Science and Technology Parks Corporation (“HKSTP”) is leading an expanded force of 14 start-ups to TechCrunch Disrupt SF 2018 in San Francisco, the United States. The line-up is nearly twice the size of last year’s delegation and it is a tangible evidence that HKSTP’s significantly increased investment in R&D is paying off, with a host of commercially-viable solutions to be showcased at the global event.

The innovative solutions confirm that HKSTP’s strategic focus on the technology platforms of artificial intelligence and robotics, smart city, biotechnology and healthy ageing is also bearing fruit. They include AI-powered solutions for optimising investment strategies, restaurant bookings and fashion buying experiences, as well as robotics for construction and elderly care. There are biomedical innovations such as a saliva-based self-testing solution and wearables for physical and mental wellness monitoring. Smart city applications include technologies to reduce fleet driver accidents, improve logistics for e-commerce and help children and parents stay connected. 

The winner of HKSTP’s 2017 Elevator Pitch Competition, Cathay Photonics, which impressed judges with its sapphire-based, ultra-hard and scratch-proof thin film for electronic devices, is also part of the delegation to Disrupt SF 2018.

HKSTP is the city’s leading incubator and nurture base. Its incubation programmes are among the most comprehensive in the region, covering biotechnology, IoT, FinTech, robotics and electronics. The programmes offer a complete roadmap for start-ups, from pre-incubation to go-to-market, nurturing and supporting start-ups at different stages.

“Taking Hong Kong start-ups overseas to promote their R&D results and connect them with international counterparts and investors at major global events is a key initiative of HKSTP,” said Albert Wong, Chief Executive Officer of HKSTP. “The technologies from our 14 start-ups demonstrate that Hong Kong Science Park is a globally competitive base where disruptive ideas have room to grow and take hold.”

“As well as showcasing the R&D results of the start-ups, we’re keen to impress upon disruptors from around the world that Hong Kong is committed to supporting innovators who have outside-the-box ideas. With the recent HK$10 billion boost in government funding to expand the city’s technology R&D infrastructure and support services, HKSTP is ready to welcome innovators and investors to connect with Hong Kong’s vibrant innovation and technology ecosystem, and tap opportunities in the Greater Bay Area encompassing 11 dynamic cities in southern China.”

To make the most of the trip, the Hong Kong start-ups also joined a day-long Hong Kong Technology Mission to San Francisco and Silicon Valley on September 4, prior to the start of TechCrunch Disrupt SF 2018 on September 5. The start-ups and their innovations include:

View original content:http://www.prnewswire.com/news-releases/hkstp-leads-an-expanded-start-up-delegation-to-techcrunch-disrupt-sf-2018-300706924.html